In decompensated liver cirrhosis, hypoalbuminemia still persists even after they have been treated with branched-chain amino acid (BCAA) granules. We prospectively evaluated whether BCAA enriched nutrient switched from BCAA granules would increase the serum albumin level, and consequently extend the survival time after hepatocellular carcinoma (HCC) treatment.
Introduction
Hepatocellular carcinoma (HCC) is one of the high incidence cancer in the world 1 , and its rate has also increased over the last decade. Curative treatment approaches including surgical hepatectomy, liver transplant and local treatment of radiofrequency ablation (RFA) are indicated for 30% to 60% of all HCC 1, 2 . Transcatheter arterial chemoembolization (TACE) will be used in other patients with a specific severity of liver damage, specifically, Bar- After TACE was found to be involved in HCC prognosis in recent years 6, 7 , Bolondi et al. 8 
Patients and Methods

Study Population
This study included 77 patients treated at our hospital for liver cirrhosis (LC) and HCC for which neither RFA .
Study Design and Protocol
The nutritional assessment in all patients consisted of a one-week diary of diet intake and estimation of total daily caloric intake and protein/fat/carbohydrate ratio.
Dieticians prescribed a diet limiting the total daily calorie intake to 30 to 35 kcal/kg/day and protein intake to 1.5 The study treatment was administered to only patients who had given written informed consent. This study conformed to the Declaration of Helsinki and was approved by the institutional ethical review board of our hospital.
Procedure of TACE
The application of TACE to HCC in this study is patient's Child-Pugh score 5 to 7 with total bilirubin level <2.0 mg/dL and besides nothing of ascites. As previously reported 16, 17 , a 4-Fr catheter was inserted into the left radial artery, and super selective embolization was performed on the tumor with staining on hepatic arteriography concurrently using a microcatheter in the TACE procedure. Miriplatin (miriplatin hydrate, Sumitomo Dainippon Pharma Co., Ltd, Osaka, Japan) 40 to 80 mg/body and iodized oil (Lipiodol; Lipiodol Ultrafluide, Laboratoire Guerbet, Aulnay-sous-Bois, France) were mixed at an equal ratio and injected during the embolization according to the diameter and number of tumors. Porous gelatin granules (Gelpart; Nippon Kayaku Co., Ltd, Tokyo, Japan) were used as the embolization material. Tu- 
Clinical Endpoint
The serum albumin level and branched-chain amino acid to tyrosine ratio (BTR) were measured before and after starting BCAA granules and after switching to BCAA enriched nutrient every month. In patients who switched to BCAA enriched nutrient, the change of symptoms was evaluated using the Short Form-8 (SF-8) 18 every month.
Overall survival was compared between patients who had undergone TACE and those with untreated BCLC stage B HCC to evaluate whether TACE affected the prognosis of HCC.
Statistical Analysis
Changes in the serum albumin level and BTR were analyzed using analysis of variance. The Kaplan-Meier method was used for the comparison of the survival rate between the patient groups, followed by a log-rank test.
A statistical significance level of P<0.05 and the standard statistical software (JMP Pro version 8.02 software for Windows, SAS institute, Cary, NC, USA) were used for all the analyses.
Results
Changes of Nutrition Balance
The total calorie and protein intake from meals (30 to 35 kcal/kg/day and 1.5 g/kg/day, respectively) were determined based on the average body size of Japanese cirrhosis patients. According to the dieticians' assessment, however, the mean total calorie and protein intake in 77 . Twenty-three patients who did not undergo TACE were followed without treatment for HCC. Only a subjective symptom assessment was made in these patients (Fig. 1) .
Changes of Serum Albumin and BTR
From baseline to 3 months after switching to BCAA enriched nutrient (n=39), the serum albumin level slightly increased during the treatment with BCAA granules (P=0.0682) and significantly increased after switching to BCAA enriched nutrient (P=0.0004). The change in BTR was comparable to the serum albumin level, which significantly increased after switching to BCAA enriched nutrient (P<0.0001; Fig. 2a) . On the other hand, there were no remarkable change of serum albumin level (P= Fig. 2 Changes of Albumin level and branched-chain amino acid to tyrosine ratio (BTR): Sequential changes in serum albumin level and BTR at three months using branched-chain amino acid (BCAA) granules and after 3 months switched BCAA enriched nutrient. Albumin level and BTR were significantly increased in parallel from baseline after switching BCAA enriched nutrient (P<0.0001) (2a). There were 38 patients with increased serum albumin level and BTR after 3 months using BCAA granules, but further improvements were not observed significantly (P=0.6722, P=0.0721) (2b).
0.6722) and BTR (P=0.0721) after 3 months or later in albumin increasing group (n=38; Fig. 2b ). (Fig. 3) .
Changes of Child-Pugh Score
Changes of Symptom
Change of symptoms after using BCAA was evaluated based on SF-8. Although not significant, only edema tented to improve, decreasing from 53.2% to 39.0% after using BCAA granules (P=0.0754). After switching to BCAA enriched nutrient, ascites (P=0.001), edema (P< 0.0001), and muscle cramp in lower limbs (P=0.0007)
were significantly improved. General fatigue and sleep disturbance did not improve with either of the BCAA products ( Table 3) .
Overall Survival Analysis
Overall survival was compared between 54 patients who underwent TACE for HCC and 23 patients who were followed without treatment. The 1-and 3-year sur- Fig. 3 Changes of Child-Pugh score: Finally, patients in Child-Pugh scores of 5 to 7 accounted for more than 80% of branched-chain amino acid enriched nutrient switching group (n=39) after 6 months (P=0.0020). But there were no significant changes throughout the course of branched-chain amino acidTa granules continuing group (n=38) (P=0.1387), and was no remarkable distribution of Child-Pugh score over the last three-month period. Child-Pugh sore 5 6 7 8 9 *P =0.0020 (versus baseline) * Table 3 Changes in symptoms after using branched-chain amino acid products (n=77)
Symptom
Patient baseline number
Branched-chain amino acid granules 3 months after vival rates were 97% and 56% in the TACE group, respectively. In the no treatment group, the 1-year survival rate was relatively good (92%) but the 3-year survival rate was low (12%). The survival time was significantly extended in the TACE group (P<0.0001) (Fig. 4a) . This trend was almost similar in BCAA enriched mixture switching group (P=0.0004) (Fig. 4b) and in BCAA granules continuing group (P=0.0001) (Fig. 4c) . In undergoing TACE group, the 1-and 3-year survival rate was 100%
and 61% in the BCAA mixture switching patients, on the other hand 95% and 44% in BCAA granules continuing patients (P=0.0294).
Discussion
After being developed in Japan
19
, TACE was shown to be effective in 2 randomized controlled trials 6, 20 . The procedure is now defined as an essential treatment for HCC together with hepatectomy and RFA in the BCLC staging system 21 . In practice, the curative treatment including hepatectomy and RFA is indicated only for 30% to 60% of The significance of metabolic syndrome has been emphasized in recent years in Japan and worldwide. Obesity is a risk factor for progression of LC 25 . A recent study found more than 50% of LC patients were in the state of protein-energy malnutrition but about 30% of them had an estimated BMI of ! 25 24 . A multicenter randomized controlled study in patients with decompensated LC identified obesity as a risk factor for HCC 26 . Supplementation with BCAA enriched nutrient containing balanced vitamin/mineral/sugar/fat is quite beneficial for LC patients compared with BCAA granules since the nutrients are easily depleted. However, accurate "partial replacement" should be ensured to avoid excess in total daily calorie intake when giving BCAA enriched nutrient (210 kcal/pack) twice a day, including late evening snack.
This study had the following limitations. First, the total calorie intake from meals and BCAA were self-reported by patients and may not have been accurate. We need more patient's support for BCAA treatment adherence to be successful 27 . Second, this study was prospectively designed but unfortunately failed to stratify the patients with BCLC stage B HCC because of the small sample size of 77 from a single institution. We concluded that BCAA-rich formula was beneficial, it can't deny the possibility that "carry-over" effect of BCAA granules might be present in BCAA-rich formula period. But randomization at 3 months in unchanged albumin group was not appropriate approach in terms of disadvantage to improvement in liver damages.
Third, TACE was performed in the aforementioned procedure in this study. The treatment outcome may have been better if the other procedure reported in a recent study 28 had been used.
In conclusion, the serum albumin level is expected to be low especially when decompensated LC is diagnosed based on mild edema. Therefore, the amino-acid balance should always be evaluated based on the Fischer ratio or BTR in patients with decompensated LC for timely aggressive nutritional intervention. Early partial replacement with BCAA enriched nutrient, to ensure high Fischer ratio protein in the patient's diet may consequently improve the treatment outcome of HCC.
